Index RUT
P/E -
EPS (ttm) -5.42
Insider Own 2.33%
Shs Outstand 96.44M
Perf Week -6.10%
Market Cap 1.93B
Forward P/E -
EPS next Y -5.64
Insider Trans -2.33%
Shs Float 94.19M
Perf Month -23.76%
Income -481.19M
PEG -
EPS next Q -1.38
Inst Own 88.45%
Short Float 15.49%
Perf Quarter -20.21%
Sales 36.27M
P/S 53.23
EPS this Y -2.45%
Inst Trans -0.30%
Short Ratio 9.47
Perf Half Y -24.85%
Book/sh 11.29
P/B 1.77
EPS next Y -1.53%
ROA -34.11%
Short Interest 14.59M
Perf Year -44.80%
Cash/sh 9.46
P/C 2.12
EPS next 5Y 30.00%
ROE -42.10%
52W Range 20.78 - 47.48
Perf YTD -34.34%
Dividend Est. -
P/FCF -
EPS past 5Y -22.30%
ROI -41.96%
52W High -57.83%
Beta 1.85
Dividend TTM -
Quick Ratio 8.67
Sales past 5Y 12.09%
Gross Margin 75.26%
52W Low -3.66%
ATR (14) 1.22
Dividend Ex-Date -
Current Ratio 8.67
EPS Y/Y TTM 12.31%
Oper. Margin -1420.51%
RSI (14) 24.54
Volatility 5.04% 4.49%
Employees 526
Debt/Eq 0.11
Sales Y/Y TTM -30.40%
Profit Margin -1326.51%
Recom 1.54
Target Price 69.57
Option/Short Yes / Yes
LT Debt/Eq 0.09
EPS Q/Q -4.64%
Payout -
Rel Volume 0.94
Prev Close 21.17
Sales Surprise -115.04%
EPS Surprise -1.49%
Sales Q/Q -114.12%
Earnings Feb 22 BMO
Avg Volume 1.54M
Price 20.02
SMA20 -16.73%
SMA50 -25.31%
SMA200 -35.14%
Trades
Volume 1,454,657
Change -5.43%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-23-24 Downgrade
Goldman
Buy → Neutral
$136 → $32
Feb-15-24 Initiated
Wolfe Research
Peer Perform
Apr-13-23 Initiated
Canaccord Genuity
Buy
$66
Mar-21-23 Initiated
Bernstein
Outperform
$54
Mar-14-23 Upgrade
BMO Capital Markets
Market Perform → Outperform
$54 → $57
Feb-01-23 Initiated
Cantor Fitzgerald
Overweight
$67
Jan-24-23 Upgrade
Citigroup
Sell → Neutral
$48 → $39
Jan-19-23 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Oct-11-22 Initiated
Morgan Stanley
Overweight
$84
Sep-21-22 Initiated
JP Morgan
Overweight
$85
Sep-01-22 Initiated
Citigroup
Sell
$50
Jun-17-22 Initiated
BMO Capital Markets
Market Perform
$54
Jun-16-22 Initiated
BofA Securities
Buy
$70
Apr-28-22 Initiated
Credit Suisse
Outperform
$100
Feb-18-22 Initiated
William Blair
Outperform
$144
Feb-07-22 Upgrade
Oppenheimer
Perform → Outperform
$145 → $150
Jan-31-22 Initiated
Cowen
Outperform
Jan-07-22 Initiated
Piper Sandler
Overweight
$171
Oct-05-21 Initiated
Guggenheim
Buy
$170
Sep-24-21 Initiated
Stifel
Buy
$173
Show Previous Ratings
Apr-25-24 11:21AM
10:01AM
Apr-14-24 05:55AM
Apr-12-24 04:50AM
Apr-09-24 04:50AM
05:55AM
Loading…
Mar-28-24 05:55AM
Mar-21-24 05:29PM
04:19PM
Mar-19-24 01:06PM
Mar-18-24 07:30AM
Mar-09-24 09:45AM
Mar-06-24 10:35AM
Mar-01-24 01:43PM
Feb-29-24 05:50AM
Feb-28-24 09:30AM
11:55AM
Loading…
Feb-27-24 11:55AM
09:35AM
Feb-23-24 12:22PM
11:12AM
09:55AM
Feb-22-24 10:53PM
(Thomson Reuters StreetEvents)
08:12AM
07:30AM
Feb-20-24 05:02AM
Feb-17-24 01:59AM
Feb-15-24 10:00AM
07:30AM
06:20AM
Feb-14-24 07:30AM
Feb-13-24 06:05AM
05:09PM
Loading…
Feb-10-24 05:09PM
Feb-08-24 01:15PM
Feb-07-24 11:50AM
Feb-05-24 05:25AM
Jan-31-24 05:00PM
12:28PM
Jan-30-24 05:10AM
Jan-29-24 09:35AM
Jan-27-24 01:25PM
08:55AM
Jan-24-24 07:00AM
Jan-22-24 05:41PM
Jan-21-24 08:00AM
Jan-18-24 11:50AM
Jan-13-24 06:05AM
Jan-12-24 08:44AM
Jan-08-24 07:45AM
05:52AM
Jan-05-24 10:04AM
Jan-04-24 04:01PM
12:47PM
Dec-31-23 08:45AM
Dec-27-23 06:41PM
Dec-16-23 05:00AM
Dec-13-23 05:20AM
Dec-12-23 06:00AM
Dec-10-23 11:57AM
Nov-28-23 05:30AM
Nov-24-23 07:00AM
(The Wall Street Journal)
Nov-15-23 11:07AM
Nov-14-23 07:30AM
Nov-10-23 05:38PM
06:30AM
Nov-09-23 04:06PM
03:37PM
08:29AM
07:30AM
Nov-06-23 08:02AM
(Investor's Business Daily)
Nov-02-23 07:00AM
06:45AM
Oct-30-23 03:46PM
10:00AM
Oct-28-23 07:30AM
Oct-26-23 10:02AM
07:30AM
Oct-23-23 09:40AM
08:45AM
Oct-21-23 05:00AM
Oct-19-23 11:46AM
Oct-18-23 04:10PM
(Investor's Business Daily)
07:00AM
Oct-16-23 12:39PM
10:43AM
Oct-14-23 12:20PM
Oct-13-23 08:38AM
Oct-12-23 08:57AM
Oct-10-23 02:00PM
10:07AM
Oct-06-23 04:59AM
Oct-05-23 09:15AM
Oct-04-23 09:27AM
Oct-03-23 10:07AM
07:58AM
07:08AM
07:00AM
Sep-23-23 09:45AM
Sep-10-23 08:15AM
Sep-09-23 03:59PM
Sep-06-23 02:00PM
Sep-05-23 09:52AM
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BASTA JAMES EVP, General Counsel Mar 04 '24 Sale 32.99 2,297 75,778 81,571 Mar 05 04:10 PM Clark Eliana EVP, Chief Technical Officer Mar 04 '24 Sale 32.99 605 19,959 71,470 Mar 05 04:10 PM Sepp-Lorenzino Laura EVP, Chief Scientific Officer Jan 08 '24 Sale 28.87 2,275 65,682 43,927 Jan 10 04:15 PM LEONARD JOHN M President and CEO Jan 03 '24 Sale 29.46 19,223 566,310 846,486 Jan 05 04:51 PM Lebwohl David EVP, Chief Medical Officer Jan 03 '24 Sale 29.46 5,843 172,135 54,372 Jan 05 04:50 PM Sepp-Lorenzino Laura EVP, Chief Scientific Officer Jan 03 '24 Sale 29.46 5,532 162,973 46,202 Jan 05 04:50 PM Goddard Glenn EVP, Chief Financial Officer Jan 03 '24 Sale 29.46 5,365 158,053 40,585 Jan 05 04:49 PM Clark Eliana EVP, Chief Technical Officer Jan 03 '24 Sale 29.50 4,608 135,954 40,845 Jan 05 04:44 PM Hicks Derek EVP, Chief Business Officer Jan 03 '24 Sale 29.46 3,877 114,216 36,987 Jan 05 04:46 PM BASTA JAMES EVP, General Counsel Jan 03 '24 Sale 29.46 3,805 112,095 51,474 Jan 05 04:45 PM Bhanji Muna Director Oct 31 '23 Sale 23.90 265 6,334 11,996 Nov 02 04:42 PM Bhanji Muna Director Jul 31 '23 Sale 42.33 265 11,217 12,261 Aug 02 05:19 PM Bhanji Muna Director Jul 06 '23 Sale 39.30 1,867 73,373 12,526 Jul 10 05:21 PM Clark Eliana EVP, Chief Technical Officer Jul 03 '23 Sale 40.51 360 14,584 45,146 Jul 06 03:34 PM Clark Eliana EVP, Chief Technical Officer Jun 20 '23 Option Exercise 12.27 5,000 61,350 50,146 Jun 22 05:52 PM Clark Eliana EVP, Chief Technical Officer Jun 20 '23 Sale 45.00 5,000 225,000 45,146 Jun 22 05:52 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite